// App-Quantinova.ai

: Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial

Researchers

Presenter

  • Martin Kolb

Principal Investigators

  • Athol Wells

  • Jrgen Behr

  • Luca Richeldi

  • Birgit Schinzel

  • Manuel Quaresma

  • Susanne Stowasser

  • Ganesh Raghu

  • Fernando J Martinez

Medical Centers

  • McMaster University, Hamilton, ON, Canada

  • National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and the National Heart and Lung Institute, Imperial College, London, United Kingdom,

  • Medizinische Klinik und Poliklinik V, University of Munich, LMU and Asklepios Klinik München-Gauting, Member of the German Center for Lung Research, Munich, Germany,

  • Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy.

  • HMS Analytical Software GmbH, Heidelberg, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • University of Washington, Seattle, WA, United States

  • Weill Cornell Medical College - New York - United States of America

Locations

  • Canada

  • United Kingdom

  • Germany

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

  • Sildenafil citrate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT02802345

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved